Prospective associations of interleukin‐6 and APOE allele with cognitive decline in biracial community‐dwelling older adults: The Chicago Health and Aging Project (CHAP)
Authors:
Open Access
- 21 October 2024
- journal article
- research article
- Published by Wiley in Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring
- Vol. 16 (4) , e70002
Abstract
INTRODUCTION: It is unclear whether inflammation, that is, high interleukin‐6 (IL‐6) levels, and genetic risk, that is, apolipoprotein E (APOE) ε4 allele, have a compounding effect on cognitive decline (CD).METHODS: We analyzed a subset of participants from the longitudinal cohort study, Chicago Health and Aging Project, comprising 1120 biracial community‐dwelling older adults (60% Black and 62% women), and mean follow‐up = 6.4 years. We ran adjusted mixed‐effects models on2 longitudinal CD.RESULTS: In APOE ε4 carriers, higher serum IL‐6 was not associated with the rate of CD (β = –0.0091 [standard deviation (SD) = 0.0165, p = 0.5800]). Conversely, in non‐ε4 carriers, compared to the lower tertile, those with the upper tertile of serum IL‐6 levels experienced significantly accelerated CD (β = –0.0257 [SD = 0.0084, p = 0.0023]).DISCUSSION: Even without the largest genetic risk factor for late‐onset Alzheimer's disease/Alzheimer's disease and related dementias (AD/ADRD), elevated serum IL‐6 still accelerate the rate of CD in non‐APOE ε4 carriers. Hence, interventions ameliorating inflammation may prevent AD/ADRD.Highlights: Interleukin‐6 (IL‐6) and the apolipoprotein E (APOE) ε4 allele have been separately associated with an increased risk for cognitive decline, but their interaction remains unclear. In ε4 carriers, IL‐6 was not associated with cognitive decline. However, even without the biggest genetic risk factor for Alzheimer's disease (AD), that is, APOE ε4, elevated serum IL‐6 still could confer accelerated rate of cognitive decline, with a detrimental effect half of that imposed by APOE ε4 alone. We found no racial differences in these associations. These findings contribute complementary evidence on non–APOE ε4‐dependent and non‐AD biological pathways through which cognitive decline can still be accelerated in non‐APOE ε4 carriers and highlight a specific subgroup of older adults who are at a higher risk of AD and thus may benefit from anti‐inflammatory interventions.Keywords
This publication has 40 references indexed in Scilit:
- Socioeconomic status and stress-induced increases in interleukin-6Brain, Behavior, and Immunity, 2004
- APOE Genotype and an ApoE-mimetic Peptide Modify the Systemic and Central Nervous System Inflammatory ResponseJournal of Biological Chemistry, 2003
- Design of the Chicago Health and Aging Project (CHAP)Journal of Alzheimer’s Disease, 2003
- Cognitive activity and cognitive decline in a biracial community populationNeurology, 2003
- Inflammatory markers and cognition in well-functioning African-American and white eldersNeurology, 2003
- Incidence of Alzheimer Disease in a Biracial Urban CommunityArchives of Neurology, 2003
- Interleukin-6 and risk of cognitive declineNeurology, 2002
- Interleukin-6-associated inflammatory processes in Alzheimer's disease: New therapeutic optionsNeurobiology of Aging, 1996
- Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patientsActa Neuropathologica, 1995
- Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.Journal of Lipid Research, 1990